Name | DCC-2618 |
Synonyms | CS-937 DCC2618 DCC 2618 DCC-2618 c-Kit-IN-1 N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide DCC-2618 |
CAS | 1225278-16-9 |
Molecular Formula | C26H21F2N5O3 |
Molar Mass | 489.47 |
Density | 1.40±0.1 g/cm3 (20 ºC 760 Torr) |
Boling Point | 729.7±60.0 °C(Predicted) |
pKa | 12.10±0.70(Predicted) |
Storage Condition | -20℃ |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.043 ml | 10.215 ml | 20.43 ml |
5 mM | 0.409 ml | 2.043 ml | 4.086 ml |
10 mM | 0.204 ml | 1.022 ml | 2.043 ml |
5 mM | 0.041 ml | 0.204 ml | 0.409 ml |
biological activity | PDGFR inhibitor 1 is an orally active Kit (c-Kit) and PDGFR inhibitor, it has potential anti-tumor activity. It also inhibits several other kinases, including VEGFR2, TIE2, PDGFR-beta and CSF1R, thereby inhibiting the growth of tumor cells. |
Target | Value |